2 completed, 2 unknown, 1 active not recruiting, 1 recruiting. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Unknown 2, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Indolent Systemic Mastocytosis: new trials by email Literature Review of Indolent Systemic Mastocytosis trials Research Report on Indolent Systemic Mastocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis Elenestinib, Placebo - Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis | Phase 2 / Phase 3 | Recruiting | Blueprint Medicines Corporation | 534 | 2021-11-30 | 2026-10-07 |
| Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis TL-895, Placebo - Myelofibrosis, Indolent Systemic Mastocytosis | Phase 2 | Unknown | Telios Pharma, Inc. | 121 | 2020-10-22 | 2024-05-10 |
| Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis sarilumab, Placebo - Indolent Systemic Mastocytosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 21 | 2019-06-19 | 2024-12-17 |
| (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis Avapritinib, Placebo - Indolent Systemic Mastocytosis | Phase 2 | Active not recruiting | Blueprint Medicines Corporation | 251 | 2019-04-16 | 2026-10-02 |
| Treatment of Indolent Systemic Mastocytosis With PA101 PA101, Placebo - Mastocytosis, Systemic Mastocytosis | Phase 2 | Completed | Patara Pharma | 41 | 2015-06-01 | 2016-09-29 |
| Midostaurin in Indolent Systemic Mastocytosis Midostaurin, - Indolent Systemic Mastocytosis | Phase 2 | Unknown | University Medical Center Groningen | 20 | 2013-08-01 | 2015-01-19 |
Mastocytosis, Systemic (6) · Mastocytosis (2) · Primary Myelofibrosis (1)
Immune System Diseases (6) · Mast Cell Activation Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Connective Tissue (6) · Neoplasms, Connective and Soft Tissue (6) · Mastocytosis (4) · Bone Marrow Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Myeloproliferative Disorders (1)
avapritinib (1) · midostaurin (1) · sarilumab (1)
Blueprint Medicines Corporation (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Patara Pharma (1) · Telios Pharma, Inc. (1) · University Medical Center Groningen (1)
France (4) · Germany (4) · Italy (4) · Netherlands (4) · Spain (4) · United States (4) · Belgium (3) · Australia (2) · Brazil (2) · Denmark (2) · Norway (2) · Poland (2) · Sweden (2) · Switzerland (2) · United Kingdom (2)
Frank Siebenhaar, MD (1) · Hirsh D Komarow, M.D. (1) · J.C. Kluin-Nelemans, MD, PhD (1)
PMID 29890238, PMID 34663404, PMID 38320129, PMID 40529483, PMID 41244098, PMID 41690487
2018 (1)